Overview

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safety and tolerability of JS006 as Monotherapy and in combination with toripalimab in patients with advanced tumors who have failed standard therapies or who have no standard therapy. It is planned to enroll 69-176 patients into the study.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Junshi Bioscience Co., Ltd.